Since 2012, when CRISPR/Cas9 was found to cut specific DNA sequences like molecular scissors, the tool has been adapted to remove and add genes for lab research and to target genetic diseases such as cystic fibrosis and Huntington’s. One problem has held it back: CRISPR sometimes edits parts of the genome it was never meant to touch.

Salk Institute scientists have now built a method called Superb-seq to address that. It reads out every edit CRISPR makes, on target and off, along with the resulting changes in gene activity, in individual cells. The work, led by senior author Graham McVicker, was published in Nature Methods. 

 “What really inspired Superb-seq was a frustration with the existing state of affairs,” says McVicker. “We knew there were problems with CRISPR making unwanted edits, but also there was no good way to see what those edits were and how they affected the cell—what we wanted to see was invisible using current technologies.”

Existing approaches can locate unwanted edits but cannot say which cells carry them or how they alter cell behavior. Superb-seq combines Cas9 editing, a short DNA sequence that reports each edit, and single-cell RNA sequencing. The team tested it on 34,000 cells from three cell lines. Among 10,000 laboratory-grown human leukemia cells, it found 43 edit sites, 36 of them off target, across 5,761 edited cells. It also picked up gene expression changes that current detection methods miss, and it interpreted edit effects better than Perturb-seq, an earlier method that measures gene expression and guide RNAs but not the edits themselves.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

Co-first author Brad Balderson explained why that matters. “In some cases, off-target edits could disrupt key genes that protect against cancer or other unhealthy cellular states,” adding “That is why it’s essential to not only know what off-target edits are being made, but to know in what cells they occurred and whether they have any impact on activity that could result in disorder or disease. That ability to distinguish between likely benign versus important off-target edits is a key layer of information Superb-seq gives us.”

The team sees four main uses: basic research, drug development, personalized medicine, and training machine learning models. Because genomes differ between people, genetic differences can create new off-target edits, and Superb-seq could show those edits and their effects for an individual to help pick the safest treatment. The researchers also note that current training data lack single-cell edit outcomes, which limits what artificial intelligence models can learn, and that better data matter as much as more data. 

Co-first author Michael Lorenzini honed in on the research literature. “There are tens of thousands of papers that use CRISPR to study different aspects of biology. Superb-seq could reveal the extent to which off-target edits color all those findings. And beyond basic discovery settings, our tool could be immensely helpful in establishing the safety of genome therapy candidates early on in development. Superb-seq could be used to profile candidates and learn what their off-target edits are, as well as their effects.”